# Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate

> **NCT00525213** · PHASE2 · COMPLETED · sponsor: **OxyPharma** · enrollment: 224 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Rob 803
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00525213
- **Lead sponsor:** OxyPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2009-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525213, "Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00525213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*